President of The American Society of Clinical Oncology Says "Pretty Incredible Results" LINK
Experimental Gilead drug effective in early-stage leukemia trial Reuters
Wed May 15, 2013 5:59pm EDT
By Deena Beasley
May 15 (Reuters) - An experimental drug from Gilead Sciences Inc shrank tumors in half of leukemia patients whose cancer had returned, according to an early-stage trial that represents a new foray into oncology by the world's biggest seller of HIV medications.
The pill, idelalisib, is part of a new class of medications designed to selectively block a type of protein known to promote tumor growth in patients with chronic lymphocytic leukemia (CLL) and other types of blood cancer.
The "pretty incredible" results illustrate how a growing understanding of tumor biology is helping researchers develop promising new targeted drugs, said Dr Sandra Swain, president of the American Society of Clinical Oncology, which will feature the research at its conference in Chicago later this month.